1. Home
  2. ATYR vs ZYXI Comparison

ATYR vs ZYXI Comparison

Compare ATYR & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • ZYXI
  • Stock Information
  • Founded
  • ATYR 2005
  • ZYXI 1996
  • Country
  • ATYR United States
  • ZYXI United States
  • Employees
  • ATYR N/A
  • ZYXI N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ATYR Health Care
  • ZYXI Health Care
  • Exchange
  • ATYR Nasdaq
  • ZYXI Nasdaq
  • Market Cap
  • ATYR 451.3M
  • ZYXI 72.3M
  • IPO Year
  • ATYR 2015
  • ZYXI N/A
  • Fundamental
  • Price
  • ATYR $5.30
  • ZYXI $2.22
  • Analyst Decision
  • ATYR Strong Buy
  • ZYXI Buy
  • Analyst Count
  • ATYR 6
  • ZYXI 3
  • Target Price
  • ATYR $20.20
  • ZYXI $6.00
  • AVG Volume (30 Days)
  • ATYR 3.7M
  • ZYXI 258.2K
  • Earning Date
  • ATYR 08-12-2025
  • ZYXI 07-24-2025
  • Dividend Yield
  • ATYR N/A
  • ZYXI N/A
  • EPS Growth
  • ATYR N/A
  • ZYXI N/A
  • EPS
  • ATYR N/A
  • ZYXI N/A
  • Revenue
  • ATYR N/A
  • ZYXI $172,401,000.00
  • Revenue This Year
  • ATYR $960.85
  • ZYXI N/A
  • Revenue Next Year
  • ATYR $1,283.47
  • ZYXI $19.55
  • P/E Ratio
  • ATYR N/A
  • ZYXI N/A
  • Revenue Growth
  • ATYR N/A
  • ZYXI N/A
  • 52 Week Low
  • ATYR $1.58
  • ZYXI $1.66
  • 52 Week High
  • ATYR $5.98
  • ZYXI $10.62
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 56.28
  • ZYXI 42.75
  • Support Level
  • ATYR $5.07
  • ZYXI $2.31
  • Resistance Level
  • ATYR $5.58
  • ZYXI $2.72
  • Average True Range (ATR)
  • ATYR 0.39
  • ZYXI 0.18
  • MACD
  • ATYR -0.04
  • ZYXI -0.03
  • Stochastic Oscillator
  • ATYR 64.20
  • ZYXI 6.25

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About ZYXI Zynex Inc.

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

Share on Social Networks: